References
- Smallpox requirements for smallpox vaccine (Requirements for Biological Substances No. 5) revised 1965. In: Technical Report Series 323, Annex 4. WHO, Geneva, Switzerland (1966).
- OPV recommendations for the production and control of poliomyelitis vaccines (oral) revised 1999. In: Technical Report Series 904, Annex 1. WHO, Geneva, Switzerland (1999).
- Recommendations for the production and control of influenza vaccine (inactivated). In: Technical Report Series 927, Annex 3. WHO, Geneva, Switzerland (2005).
- Baxby D. Smallpox Vaccine, Ahead of Its Time. The Jenner Museum, Berkeley, UK (2001).
- Recommendations for the production and quality control of smallpox vaccines revised 2003. In: Technical Report Series 926, Annex 1. WHO, Geneva, Switzerland (2003).
- Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1, 115–118 (1973).
- Sabin AB. Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science 123(3209), 1151–1157 (1956).
- Nkowane BM, Wassilak SG, Orenstein WA et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 257(10), 1335–1340 (1987).
- Markers of poliovirus strains isolated from cases temporally associated with the use of live poliovirus vaccine: report on a WHO collaborative study. J. Biol. Stand. 9, 163–184 (1981).
- Boulger LR, Marsden SA, Magrath DI, Taffs LF, Schild GC. Comparative monkey neurovirulence of Sabin type III poliovirus vaccines. J. Biol. Stand. 7(2), 97–111 (1979).
- Sweet BH, Hilleman MR. The vacuolating virus, S.V. 40. Proc. Soc. Exp. Biol. Med. 105, 420–427 (1960).
- Shah K, Nathanson N. Human exposure to SV40: review and comment. Am. J. Epidemiol. 103(1), 1–12 (1976).
- Sangar D, Pipkin PA, Wood DJ, Minor PD. Examination of poliovirus vaccine preparations for SV40 sequences. Biologicals 27(1), 1–10 (1999).
- Baylis SA, Shah N, Jenkins A, Berry NJ, Minor PD. Simian cytomegalovirus and contamination of oral poliovirus vaccines. Biologicals 31(1), 63–73 (2003).
- Eberle R, Hilliard J. The simian herpesviruses. Infect. Agents Dis. 4(2), 55–70 (1995).
- Smith CE, Simpson DI, Bowen ET, Zlotnik I. Fatal human disease from vervet monkeys. Lancet 2(7526), 1119–1121 (1967).
- Patriarca PA, Laender F, Palmeira G et al. Randomised trial of alternative formulations of oral poliovaccine in Brazil. Lancet 1(8583), 429–433 (1988).
- Smith GJ, Vijaykrishna D, Bahl J et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459(7250), 1122–1125 (2009).
- Minor PD. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin. Infect. Dis. 50(4), 560–565 (2010).
- Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5(3), 237–247 (1977).
- Ennis FA, Mayner RE, Barry DW et al. Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J. Infect. Dis. 136(Suppl.), S397–S406 (1977).
- Palache AM, Beyer WE, Lüchters G, Völker R, Sprenger MJ, Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 11(9), 892–908 (1993).
Websites
- WHO. Guidelines to assure the quality safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. www.who.int/biologicals/
- Edward Jenner (1749–1823). The Three Original Publications on Vaccination Against Smallpox. The Harvard Classics, 1909–1914. www.bartleby.com.
- WHO. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks: proposed replacement of TRS 878, Annex 1. www.who.int/biologicals